Chouinard G, Annable L, Bradwejn J
Psychopharmacology (Berl). 1984;83(1):126-8. doi: 10.1007/BF00427436.
In a 6-week open-label study, ten newly admitted depressed patients were treated with tomoxetine , a selective inhibitor of noradrenaline reuptake. After 7 days of drug washout, patients were given an initial dose of 40 mg/day which was gradually increased to a maximum of 70 mg/day (median 50 mg/day). There was a statistically (P less than 0.001) and clinically significant improvement in the mean symptomatology of the patients measured on the Hamilton Depression Rating Scale. The drug had an early onset of action, a specific effect on mood, and no sedative properties.
在一项为期6周的开放标签研究中，10名新入院的抑郁症患者接受了托莫西汀治疗，托莫西汀是一种去甲肾上腺素再摄取选择性抑制剂。在停药7天后，患者开始服用初始剂量为40毫克/天的药物，该剂量逐渐增加至最大70毫克/天（中位数为50毫克/天）。根据汉密尔顿抑郁量表测量，患者的平均症状在统计学上（P小于0.001）和临床上均有显著改善。该药物起效早，对情绪有特定作用，且无镇静作用。
